Eli Lilly and Company (LLY) Announces Updated Meaningful Data on Breast Cancer Treatment

Eli Lilly and Company (NYSE:LLY) is one of the best forever stocks to buy according to hedge funds. On December 15, Goldman Sachs lifted its price target on Eli Lilly and Company (NYSE:LLY) to $1,145 from $951 while reiterating a Buy rating on the stock. Eli Lilly and Company (LLY) Announces Updated Meaningful Data on Breast Cancer Treatment Pixabay/Public Domain On December 12, Eli Lilly and Company provided updated data for its oral estrogen receptor antagonist Inluriyo (imlunestrant) currently in Pha ...